Last 47 quarters of trend data · Healthcare · Drug Discovery Platforms
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -0.36 | — | — | — | 0.65 | — | — | 7.44 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.53 | 3.86 | 5.61 | 7.64 | 7.96 | 2.62 | 0.87 | 1.97 | 2.56 | 13.67 | 2.27 | 18.38 | 1.91 | 18.49 | 10.19 | 109.33 | 183.53 | 254.21 | 564.81 | 542.89 | 1785.37 |
| — | +47.5% | +545.7% | +287.2% | +210.8% | -80.9% | -61.6% | -89.3% | +34.4% | -26.0% | -77.8% | -83.2% | -99.0% | -92.7% | -98.2% | -79.9% | -89.7% | -90.1% | -61.7% | -52.5% | +111.2% | |
| P/B Ratio | 0.18 | 0.93 | 0.94 | 0.80 | 0.58 | 0.75 | 0.69 | 0.86 | 1.46 | 1.66 | 1.50 | 1.48 | 0.80 | 1.55 | 0.92 | 8.30 | 8.93 | 6.99 | 9.78 | 10.65 | 15.24 |
| — | +24.2% | +36.9% | -6.5% | -60.5% | -55.0% | -54.2% | -42.2% | +81.9% | +6.7% | +63.1% | -82.1% | -91.0% | -77.8% | -90.6% | -22.1% | -41.4% | -61.4% | -59.1% | -62.3% | -20.0% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -6.3% | -2.3% | 61.1% | -627.4% | 49.7% | 84.6% | 34.0% | 53.1% | 40.1% | 44.5% | 92.6% | 31.1% | 86.4% | 29.5% | 49.8% | 44.8% | 74.2% | 16.0% | 31.2% | 14.1% | 33.1% |
| — | -102.7% | +79.8% | -1280.8% | +23.8% | +90.3% | -63.3% | +70.6% | -53.6% | +50.7% | +86.1% | -30.6% | +16.4% | +84.1% | +59.4% | +217.0% | +124.2% | +209.1% | +67.7% | +893.2% | -56.6% | |
| Operating Margin | -364.2% | -703.5% | -943.1% | -1659.9% | -873.1% | -347.4% | -168.8% | -283.5% | -340.2% | -765.1% | -97.5% | -1319.7% | -111.0% | -1208.1% | -1060.2% | -573.0% | -1523.0% | -2566.3% | -3398.7% | -2794.9% | -5666.2% |
| — | -102.5% | -458.6% | -485.5% | -156.6% | +54.6% | -73.1% | +78.5% | -206.4% | +36.7% | +90.8% | -130.3% | +92.7% | +52.9% | +68.8% | +79.5% | +73.1% | +53.5% | -80.8% | -36.7% | -222.4% | |
| Net Margin | -220.2% | -509.5% | -1757.5% | -1690.8% | 1241.7% | -504.8% | -105.9% | 26.5% | -438.5% | -895.7% | -92.2% | -1142.0% | -105.8% | -1073.9% | -978.3% | -454.2% | -1404.3% | -2827.2% | -3491.6% | -2370.1% | -5039.7% |
| — | -0.9% | -1560.3% | -6479.0% | +383.2% | +43.6% | -14.8% | +102.3% | -314.6% | +16.6% | +90.6% | -151.4% | +92.5% | +62.0% | +72.0% | +80.8% | +72.1% | +38.5% | -76.1% | -2.4% | -232.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -63.3% | -25.7% | -58.8% | -36.3% | 26.2% | -36.0% | -19.0% | 3.2% | -47.4% | -23.9% | -14.3% | -20.5% | -11.9% | -23.6% | -19.8% | -8.2% | -15.6% | -17.6% | -14.0% | -11.0% | -10.3% |
| — | +28.7% | -209.5% | -1251.8% | +155.1% | -50.7% | -33.0% | +115.4% | -298.6% | -1.5% | +27.9% | -149.3% | +23.9% | -33.7% | -41.5% | +25.3% | -51.4% | -125.2% | -47.4% | +23.6% | -15.5% | |
| ROA | -28.3% | -11.3% | -30.9% | -23.0% | 12.9% | -13.1% | -7.0% | 1.1% | -18.8% | -12.4% | -7.9% | -12.1% | -7.2% | -13.7% | -11.9% | -5.2% | -11.3% | -14.3% | -11.6% | -9.2% | -8.9% |
| — | +13.9% | -342.9% | -2255.5% | +168.6% | -5.9% | +11.6% | +108.8% | -162.4% | +9.6% | +33.5% | -133.7% | +36.4% | +4.3% | -2.8% | +43.8% | -26.7% | -107.3% | -44.2% | +21.6% | -18.2% | |
| ROIC | -154.5% | -13076.8% | -173.3% | -50.9% | -13.2% | -13.3% | -20.4% | -28.1% | -20.2% | -12.2% | -13.9% | -29.0% | -14.7% | -29.5% | -29.0% | -15.7% | -28.8% | -30.1% | -22.0% | -18.7% | -17.8% |
| — | -98104.3% | -747.6% | -80.8% | +34.5% | -9.0% | -47.5% | +2.9% | -37.6% | +58.6% | +52.2% | -84.4% | +49.0% | +2.0% | -31.8% | +16.1% | -61.6% | -121.4% | -37.9% | +47.6% | +15.5% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.18 | 0.36 | 0.25 | 0.18 | 0.15 | 1.03 | 1.05 | 0.87 | 0.90 | 1.08 | 0.45 | 0.40 | 0.32 | 0.38 | 0.42 | 0.34 | 0.31 | 0.05 | 0.05 | 0.04 | 0.04 |
| — | -64.5% | -75.7% | -78.8% | -83.8% | -5.3% | +134.0% | +116.3% | +179.7% | +185.2% | +6.6% | +17.0% | +3.3% | +712.8% | +816.7% | +714.8% | +711.7% | +50.0% | +59.8% | -1.9% | -12.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 4.54 | 3.57 | 2.79 | 4.54 | 5.11 | 1.89 | 1.06 | 1.15 | 1.09 | 1.58 | 5.06 | 4.96 | 6.25 | 5.59 | 5.86 | 6.71 | 7.30 | 6.80 | 7.58 | 8.27 | 9.72 |
| — | +89.1% | +163.7% | +293.0% | +369.5% | +19.1% | -79.1% | -76.7% | -82.6% | -71.7% | -13.7% | -26.0% | -14.4% | -17.9% | -22.7% | -18.8% | -24.9% | -46.6% | -44.4% | +54.3% | -0.6% | |
| Quick Ratio | 4.48 | 3.54 | 2.76 | 4.48 | 4.59 | 1.76 | 0.92 | 1.06 | 1.03 | 1.53 | 4.94 | 4.95 | 6.24 | 5.55 | 5.75 | 6.61 | 7.27 | 6.78 | 7.55 | 8.25 | 9.72 |
| — | +101.2% | +199.7% | +323.4% | +347.6% | +14.5% | -81.4% | -78.6% | -83.5% | -72.4% | -14.1% | -25.1% | -14.2% | -18.1% | -23.8% | -19.9% | -25.2% | -46.8% | -44.6% | +54.1% | -0.6% | |
| Interest Coverage | -7.05 | -14.53 | -0.52 | -19.21 | -5.02 | -4.62 | -5.44 | -21.76 | -1.34 | -45.93 | -22.16 | -114.37 | -34.44 | -30.40 | -12.06 | -43.61 | -27.07 | -3.51 | -7.35 | -26.35 | -51.42 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 47 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying EVGN stock.
Evogene Ltd.'s current P/E is -0.4x. The average P/E over the last 1 quarters is 0.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Evogene Ltd.'s current operating margin is -364.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Evogene Ltd.'s business trajectory between earnings reports.